For example, many of the implicated cytokines are currently targeted in other disease states, including anti-TNFα and IL-1 (i.e. via infliximab and anakinra, respectively) in inflammatory arthritis and autoinflammatory disorders, IFNγ (via JAK inhibitor tofacitinib) in rheumatoid arthritis and inflammatory bowel disease as well as anti-IL-6 antibody tocilizumab in rheumatoid arthritis, juvenile idiopathic arthritis and severe COVID-19 (225). Here, IL1B is linked to rheumatoid arthritis.